Precision Medicine Program for CDKL5 Disorders: Therapeutic Screening Using Human iPSC Models

PI: Roy Perlis, MD, MSC

Institution: Massachusetts General Hospital

CDKL5 Statistics

Institutions Awarded

19

Countries Awarded

4

# of Awards

24

Total Amount

$3,497,638

We will utilize patient-derived cellular models to develop scalable small molecule assays for therapeutic discovery in CDKL5. Specifically, we will characterize neural progenitor cells, differentiated neurons, and other neural cells derived from induced pluripotent stem cells in terms of expression, metabolism, and morphology. We will then attempt to rescue these phenotypes with small molecules.